News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,038 Results
Type
Article (3717)
Company Profile (2)
Press Release (9319)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (3289)
Career Advice (80)
Deals (633)
Drug Delivery (47)
Drug Development (2310)
Employer Resources (7)
FDA (800)
Job Trends (236)
News (7220)
Policy (1239)
Tag
Academia (82)
Accelerated approval (10)
Adcomms (30)
Allergies (7)
Alliances (827)
ALS (16)
Alzheimer's disease (95)
Antibody-drug conjugate (ADC) (59)
Approvals (597)
Artificial intelligence (35)
Autoimmune disease (18)
Bankruptcy (14)
Best Places to Work (163)
BIOSECURE Act (8)
Biosimilars (44)
Biotechnology (1)
Bladder cancer (16)
Brain cancer (7)
Breast cancer (38)
Cancer (429)
Cardiovascular disease (96)
Career advice (72)
Career pathing (1)
CAR-T (49)
CDC (30)
Cell therapy (93)
Cervical cancer (2)
Clinical research (1706)
Collaboration (157)
Company closure (1)
Compensation (4)
Complete response letters (32)
COVID-19 (120)
CRISPR (6)
C-suite (16)
Cystic fibrosis (9)
Data (120)
Decentralized trials (1)
Depression (20)
Diabetes (73)
Diagnostics (86)
Digital health (1)
Diversity, equity & inclusion (2)
Drug discovery (16)
Drug pricing (95)
Drug shortages (20)
Duchenne muscular dystrophy (35)
Earnings (1023)
Editorial (9)
Employer resources (6)
Events (1374)
Executive appointments (11)
FDA (843)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (65)
Gene editing (23)
Generative AI (6)
Gene therapy (122)
GLP-1 (249)
Government (392)
Guidances (16)
Healthcare (531)
HIV (10)
Huntington's disease (9)
IgA nephropathy (10)
Immunology and inflammation (136)
Immuno-oncology (14)
Indications (1)
Infectious disease (191)
Inflammatory bowel disease (19)
Inflation Reduction Act (4)
Influenza (7)
Intellectual property (4)
Interviews (18)
IPO (190)
IRA (24)
Job creations (72)
Job search strategy (56)
JPM (9)
Kidney cancer (4)
Labor market (4)
Layoffs (128)
Leadership (2)
Legal (378)
Liver cancer (10)
Longevity (3)
Lung cancer (76)
Lymphoma (29)
Machine learning (1)
Management (2)
Manufacturing (98)
MASH (35)
Medical device (221)
Medtech (221)
Mergers & acquisitions (498)
Metabolic disorders (314)
Multiple sclerosis (19)
NASH (12)
Neurodegenerative disease (70)
Neuropsychiatric disorders (32)
Neuroscience (255)
NextGen: Class of 2026 (131)
Non-profit (86)
Now hiring (2)
Obesity (239)
Opinion (16)
Ovarian cancer (10)
Pain (29)
Pancreatic cancer (9)
Parkinson's disease (19)
Partnered (1)
Patents (38)
Patient recruitment (7)
Peanut (2)
People (846)
Pharmaceutical (3)
Pharmacy benefit managers (13)
Phase 1 (432)
Phase 2 (669)
Phase 3 (803)
Pipeline (269)
Policy (122)
Postmarket research (60)
Preclinical (164)
Prostate cancer (14)
Psychedelics (16)
Radiopharmaceuticals (11)
Rare diseases (187)
Real estate (93)
Recruiting (3)
Regulatory (947)
Research institute (80)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (7)
RSV (28)
Schizophrenia (20)
Series A (17)
Series B (13)
Sickle cell disease (14)
Spinal muscular atrophy (12)
Sponsored (3)
Startups (100)
Stomach cancer (14)
Supply chain (23)
Tariffs (48)
The Weekly (4)
Vaccines (179)
Venture capital (15)
Weight loss (196)
Women's health (5)
Worklife (2)
Date
Last 7 days (29)
Last 30 days (110)
Last 365 days (1405)
2026 (133)
2025 (1435)
2024 (1431)
2023 (1160)
2022 (873)
2021 (758)
2020 (1065)
2019 (742)
2018 (596)
2017 (495)
2016 (531)
2015 (675)
2014 (416)
2013 (370)
2012 (375)
2011 (359)
2010 (292)
Location
Africa (33)
Arizona (6)
Asia (691)
Australia (266)
California (235)
Canada (50)
China (86)
Colorado (55)
Connecticut (8)
Delaware (6)
Europe (1841)
Florida (12)
Georgia (3)
Idaho (1)
Illinois (22)
India (3)
Indiana (24)
Japan (6)
Kansas (1)
Maine (2)
Maryland (7)
Massachusetts (164)
Michigan (1)
Minnesota (3)
Missouri (2)
New Jersey (50)
New York (90)
North Carolina (10)
Northern California (108)
Ohio (3)
Oklahoma (1)
Pennsylvania (15)
South America (34)
Southern California (56)
Tennessee (6)
Texas (5)
United States (745)
Utah (7)
Virginia (1)
Washington D.C. (8)
Washington State (16)
West Virginia (1)
Wisconsin (4)
13,038 Results for "tris pharma.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tri-City Cardiology Announces Care Team Growth
December 29, 2025
·
4 min read
Press Releases
Tris Pharma Announces Acceptance of New Publication Highlighting Promise of Dual NOP-MOP (dual-NMR) Agonists for the Treatment of Moderate-to-Severe Pain
January 9, 2026
·
5 min read
Press Releases
Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic Hypersomnia
December 10, 2025
·
4 min read
Press Releases
Tri-City Cardiology’s Ambulatory Surgical Center Surpasses 6,000 Procedures, Marking a Major Milestone in Outpatient Cardiovascular Care
December 30, 2025
·
3 min read
Press Releases
Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy
- First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy - Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic reactions
December 11, 2025
·
1 min read
Mergers & acquisitions
UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to go with its original suitor.
November 19, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs
October 17, 2025
·
5 min read
Press Releases
IBA signs contract for a Proteus®ONE solution to be installed at the Tri-Service General Hospital in Taiwan
April 2, 2025
·
3 min read
FDA
Tris Pharma Gets FDA Approval for Non-Stimulant ADHD Medication
Tris Pharma on Wednesday secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for attention deficit hyperactivity disorder in pediatric patients.
May 30, 2024
·
1 min read
·
Tristan Manalac
Press Releases
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
April 28, 2025
·
11 min read
1 of 1,304
Next
